

# Georgi Iskrov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2868115/publications.pdf>

Version: 2024-02-01

42  
papers

807  
citations

516561

16  
h-index

552653

26  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1116  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intervention Services for Autistic Adults: An ASDEU Study of Autistic Adults, Carers, and Professionalsâ€™ Experiences. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 1623-1639.	1.7	10
2	Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria. <i>Frontiers in Public Health</i> , 2022, 10, 822909.	1.3	6
3	Practice Patterns for Early Screening and Evaluation for Autism Spectrum Disorder Diagnosis in Bulgaria. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 778-789.	1.7	7
4	Real-World Experiences in Autistic Adult Diagnostic Services and Post-diagnostic Support and Alignment with Services Guidelines: Results from the ASDEU Study. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 4129-4146.	1.7	20
5	Autistic Adult Health and Professional Perceptions of It: Evidence From the ASDEU Project. <i>Frontiers in Psychiatry</i> , 2021, 12, 614102.	1.3	8
6	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. <i>Value in Health</i> , 2019, 22, 1283-1288.	0.1	97
7	What could gene therapies learn from orphan drugsâ€™ post-regulatory approval access in the EU?. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 407-414.	0.5	3
8	What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. <i>Value in Health Regional Issues</i> , 2019, 19, 157-162.	0.5	7
9	Schooling of Children with Rare Diseases and Disability in Europe. <i>International Journal of Disability Development and Education</i> , 2019, 66, 362-373.	0.6	11
10	Health systems for rare diseases: financial sustainability. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 270-275.	0.2	5
11	Local Anesthesia in Pediatric Patients â€“ a Review of Current and Alternative Methods, Devices and Techniques. <i>Folia Medica</i> , 2018, 60, 381-388.	0.2	9
12	Access to orphan drugs â€“ comparison across Balkan countries. <i>Health Policy</i> , 2018, 122, 583-589.	1.4	20
13	Authorsâ€™ reply to Rare diseases in Romania â€“ a response to â€˜Transposition and implementation of EU rare diseases policy in Eastern Europeâ€™. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 349-350.	0.7	0
14	Transposition and implementation of EU rare disease policy in Eastern Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 557-566.	0.7	8
15	Health Technology Assessment and Appraisal of Therapies for Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 221-231.	0.8	13
16	Whole-Genome Sequencing in Newborn Screeningâ€™ Attitudes and Opinions of Bulgarian Pediatricians and Geneticists. <i>Frontiers in Public Health</i> , 2017, 5, 308.	1.3	8
17	PP071 Health Technology Assessment In Bulgaria: A Review Of The First Fifteen Reports Assessed. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 103-104.	0.2	0
18	Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion. <i>Frontiers in Pharmacology</i> , 2016, 7, 252.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs. <i>Frontiers in Public Health</i> , 2016, 4, 214.	1.3	35
20	Ensuring Transparency and Consistency in the Value Assessment of Cancer Therapies. <i>Journal of Clinical Oncology</i> , 2016, 34, 2938-2939.	0.8	3
21	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	1.4	50
22	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	1.4	28
23	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	1.4	59
24	Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 99-108.	1.4	31
25	Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 79-87.	1.4	40
26	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	1.4	53
27	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	1.4	38
28	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	1.4	16
29	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 43-52.	1.4	35
30	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
31	Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria. <i>Balkan Medical Journal</i> , 2016, 33, 27-35.	0.3	17
32	Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia. <i>Hospital Pharmacology</i> , 2016, 3, 422-434.	0.1	2
33	Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria. <i>Frontiers in Public Health</i> , 2015, 3, 64.	1.3	9
34	National Registries of Rare Diseases in Europe: An Overview of the Current Situation and Experiences. <i>Public Health Genomics</i> , 2015, 18, 20-25.	0.6	30
35	Economic Burden And Health-Related Quality Of Life Of Patients With Cystic Fibrosis In Bulgaria. <i>Folia Medica</i> , 2015, 57, 56-64.	0.2	15
36	National Plans on Rare Diseases. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 1-22.	0.6	1

#	ARTICLE	IF	CITATIONS
37	European Network of Rare Disease Help Lines (ENRDHLs) – caller profile analysis 2013. Orphanet Journal of Rare Diseases, 2014, 9, O13.	1.2	1
38	RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Orphanet Journal of Rare Diseases, 2014, 9, O14.	1.2	1
39	Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Research and Reviews, 2014, , 1.	0.6	15
40	Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. Folia Medica, 2013, 55, 80-86.	0.2	16
41	Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy, 2012, 108, 10-18.	1.4	29
42	Autistic Adult Services Availability, Preferences, and User Experiences: Results From the Autism Spectrum Disorder in the European Union Survey. Frontiers in Psychiatry, 0, 13, .	1.3	2